Richard Larson, MD, Hematology, Chicago, IL, University of Chicago Medical Center

RichardALarsonMD

Hematology Chicago, IL

Professor of Medicine, University of Chicago Medicine

Dr. Larson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Larson's full profile

Already have an account?

  • Office

    5841 S. Maryland Avenue
    University of Chicago Medicine, MC-2115
    Chicago, IL 60637
    Phone(773) 702-4400
    Fax(773) 702-3002
  • Is this information wrong?

Summary

  • Dr. Richard Larson is a hematologist-oncologist in Chicago, IL, and is affiliated with University of Chicago Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice >40 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemia, chemotherapy, hematologic oncology, marrow transplantation and cellular therapy, and aplastic anemia.

Education & Training

  • University of Chicago
    University of ChicagoFELLOWSHIP
  • University of Chicago
    University of ChicagoRESIDENCY
  • Stanford University School of Medicine
    Stanford University School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1978 - 2020
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
    Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
    Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
    Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • 1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaDecember 02, 2019
  • Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology Research
    Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology ResearchAugust 13, 2019

Professional Memberships

Hospital Affiliations